Taiwan's ScinoPharm forges link for biosimilars production with US firm
This article was originally published in Scrip
Executive Summary
Taiwan's ScinoPharm is to make an investment in the US firm Tanvex Biologics, with the intention of building up joint capacity for the manufacture of biosimilars in the US market.